{
  "scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Trial_Design": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Participants": {
        "score": 1,
        "evidence": "distal segments of radial arteries obtained by no-touch technique from coronary artery bypass graft (CABG) patients (n=10)"
      },
      "Intervention": {
        "score": 2,
        "evidence": "compare the efficacy of two different papaverine concentrations (0.5 mg/ml and 2 mg/ml)"
      },
      "Objective": {
        "score": 1,
        "evidence": "The aim of this study was to compare the efficacy of two different papaverine concentrations (0.5 mg/ml and 2 mg/ml) for vasospasm prevention and their impact on endothelium integrity."
      },
      "Method_Outcome": {
        "score": 1,
        "evidence": "The vasodilatory effect of papaverine (concentrations of 0.5 mg/ml and 2 mg/ml) was assessed in vitro"
      },
      "Randomisation_Allocation": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Blinding": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Number_Randomised": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Number_Analysed": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Result_Outcome": {
        "score": 2,
        "evidence": "2 mg/ml papaverine concentration showed stronger vasodilatatory effect than 0.5 mg/ml, but it caused significantly higher endothelial damage."
      },
      "Harms": {
        "score": 1,
        "evidence": "it caused significantly higher endothelial damage"
      },
      "Trial_Registration": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Funding": {
        "score": 0,
        "evidence": "Not reported"
      }
    },
    "total_score": 8,
    "max_score": 25
  },
  "model": "gpt-4o"
}